Amarin Corp Plc (AMRN)

[sts66]

Something doesn't look right on that chart - as script count grows, and production efficiency should be decreasing costs, along with annual increases in retail price, the Rev to Rx number goes down - inversely correlated to script count - should be the opposite IMO. Those $186 and $165'ish Revs per Rx at scripts between 200k-400k are serious outliers - and half the data points in that 0-400k scripts are above the trendline. Just weird too make less money with the more you sell.